Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Jul 2020

Rios-Romenets Silvia, Lopera Francisco, Sink Kaycee M, Hu Nan, Lian Qinshu, Guthrie Heather, Smith Jillian, Cho William, Mackey Howard, Langbaum Jessica B, Thomas Ronald G, Giraldo-Chica Margarita, Tobon Carlos, Acosta-Baena Natalia, Muñoz Claudia, Ospina Paula, Tirado Victoria, Henao Eliana, Bocanegra Yamile, Chen Kewei, Su Yi, Goradia Dhruman, Thiyyagura Pradeep, VanGilder Paul S, Luo Ji, Ghisays Valentina, Lee Wendy, Malek-Ahmadi Michael H, Protas Hillary D, Chen Yinghua, Quiroz Yakeel T, Reiman Eric M, Tariot Pierre N

Abstract excerpt

INTRODUCTION: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo-controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60-year-old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non-carriers who receive placebo. METHODS: Of the 252 enrolled, we present data on a total of 242 mutation carriers and non-carriers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Cognition

Share to Mutation

Share to Neuropsychological Tests

Share to Presenilin-1

Source

Open in PubMed Open full text

Identifiers

PMID: 32418361
DOI: 10.1002/alz.12109
PMCID: PMC7819133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.PMID 32418361Read ↗

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read ↗

The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.Semantic proximity Read ↗

Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort.Semantic proximity Read ↗

Cognitive Outcomes in Autosomal-Dominant Alzheimer's Disease: A Comprehensive Review from a Colombian Kindred with the Presenilin-1 E280A Mutation.Semantic proximity Read ↗

Dominantly Inherited Alzheimer Network: facilitating research and clinical trialsSemantic proximity Read ↗

The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.Semantic proximity Read ↗

The PREVENT-AD cohort: accelerating Alzheimer’s disease research and treatment in Canada and beyondSemantic proximity Read ↗

Developing an international network for Alzheimer’s research: the Dominantly Inherited Alzheimer NetworkSemantic proximity Read ↗

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's diseaseSemantic proximity Read ↗

Associations of plasma biomarkers with age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred.Semantic proximity Read ↗

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.